Trinity Biotech (TRIB) Common Equity (2009 - 2025)

Trinity Biotech (TRIB) has reported Common Equity for 17 consecutive years, with -$72.0 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 104.6% year-over-year to -$72.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$72.0 million (down 104.6% YoY) and the FY2025 annual result came in at -$72.0 million, down 104.6% from the prior year.
• Common Equity fell to -$72.0 million in Q4 2025 per TRIB's latest filing, from -$49.5 million in the prior quarter.
• Over the last five years, Common Equity for TRIB reached as high as $15.8 million in Q2 2022 and fell as low as -$72.0 million in Q4 2025.
• A 5-year average of -$15.7 million and a median of -$9.0 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity soared 1204.12% — and 2023, when it plunged 1000.6%.
• Year by year, Common Equity stood at -$319000.0 in 2021, then plunged by 582.13% to -$2.2 million in 2022, then tumbled by 1000.6% to -$23.9 million in 2023, then sank by 46.9% to -$35.2 million in 2024, then sank by 104.6% to -$72.0 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered -$72.0 million, -$49.5 million, and -$35.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.